Breaking Finance News

A statement released earlier today by H.C. Wainwright about Aerie Pharma (NASDAQ:AERI) bumps the target price to $66.00

Boasting a price of $34.12, Aerie Pharma (NASDAQ:AERI) traded 2.15% lower on the day. The last close is up 101.34% relative to the 200-day average, compared to the S&P 500 which has decreased -0.01% over the same period. The company has logged a 50-day average of $20.33 and two hundred day average of $16.95. 2,543,849 shares of AERI were exchanged, up from ann avg. volume of 874,639

H.C. Wainwright raised the estimated target of Aerie Pharma (NASDAQ:AERI) to $66, reporting a possible upside of 0.93%,

Previously on 9/15/2016, Cantor Fitzgerald reported about Aerie Pharma(NASDAQ:AERI) bumped the target price from $44.00 to $50.00. At the time, this indicated a possible upside of 1.37%.

Recent Performance Graph:

Aerie Pharma (NASDAQ:AERI)

A total of 7 firms have reported on the stock. Three firms rate the company a strong buy, three analysts rate the stock a buy, 0 analysts rate the company a hold, 0 rate the stock to underperform, and finally 0 firmsrate the company as sell with a consensus target price of $45.71

With a market cap of $0.0, Aerie Pharma has a P/E of 0 with a 52 week low of $10.82 and a 52 week high of $35.32.

Brief Synopsis On Aerie Pharma (NASDAQ:AERI)

Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan. Its product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Rhopressa is a once-daily eye drop and a triple-action netarsudil ophthalmic solution. The active ingredient in Rhopressa acts through the inhibition of both Rho Kinase (ROCK) and norepinephrine transporter (NET). Roclatan is a once-daily, quadruple-action product candidate and is a fixed-dose combination of Rhopressa and latanoprost, and which is a prescribed drug for the treatment of patients with glaucoma. The Company is engaged in conducting Phase III clinical trials for Rhopressa and Roclatan.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *